AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wexler, H. M.
Right arrow Articles by Finegold, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wexler, H. M.
Right arrow Articles by Finegold, S. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2002, p. 3669-3675, Vol. 46, No. 11
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.11.3669-3675.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

In Vitro Activities of Faropenem against 579 Strains of Anaerobic Bacteria

Hannah M. Wexler,1,2* Denise Molitoris,2 Shahera St. John,2 Ann Vu,2 Erik K. Read,2 and Sydney M. Finegold1,2,3,4

Department of Medicine, Immunology and Molecular Genetics, University of California Los Angeles School of Medicine, Los Angeles, California 90024,1 Research Services, Veterans Administration Greater Los Angeles Healthcare System, Los Angeles, California 90073,2 Medical Services, Veterans Administration Greater Los Angeles Healthcare System, Los Angeles, California 90073,3 Department of Microbiology, Immunology and Molecular Genetics, University of California Los Angeles School of Medicine, Los Angeles, California 900244

Received 25 October 2001/ Returned for modification 24 January 2002/ Accepted 6 August 2002

The activity of faropenem, a new oral penem, was tested against 579 strains of anaerobic bacteria by using the NCCLS-approved reference method. Drugs tested included amoxicillin-clavulanate, cefoxitin, clindamycin, faropenem, imipenem, and metronidazole. Of the 176 strains of Bacteroides fragilis group isolates tested, two isolates had faropenem MICs of 64 µg/ml and imipenem MICs of >32 µg/ml. Faropenem had an MIC of 16 µg/ml for an additional isolate of B. fragilis; this strain was sensitive to imipenem (MIC of 1 µg/ml). Both faropenem and imipenem had MICs of <=4 µg/ml for all isolates of Bacteroides capillosus (10 isolates), Bacteroides splanchnicus (13 isolates), Bacteroides ureolyticus (11 isolates), Bilophila wadsworthia (11 isolates), Porphyromonas species (42 isolates), Prevotella species (78 isolates), Campylobacter species (25 isolates), Sutterella wadsworthensis (11 isolates), Fusobacterium nucleatum (19 isolates), Fusobacterium mortiferum/varium (20 isolates), and other Fusobacterium species (9 isolates). Faropenem and imipenem had MICs of 16 to 32 µg/ml for two strains of Clostridium difficile; the MICs for all other strains of Clostridium tested (69 isolates) were <=4 µg/ml. Faropenem had MICs of 8 and 16 µg/ml, respectively, for two strains of Peptostreptococcus anaerobius (MICs of imipenem were 2 µg/ml). MICs were <=4 µg/ml for all other strains of gram-positive anaerobic cocci (53 isolates) and non-spore-forming gram-positive rods (28 isolates). Other results were as expected and reported in previous studies. No metronidazole resistance was seen in gram-negative anaerobes other than S. wadsworthensis (18% resistant); 63% of gram-positive non-spore-forming rods were resistant. Some degree of clindamycin resistance was seen in most of the groups tested.


* Corresponding author. Mailing address: Wadsworth Anaerobe Laboratory, Bldg. 304, Room E3-224, VAGLAHS 691/151J, Los Angeles, CA 90073. Phone: (310) 268-3404. Fax: (310) 268-4458. E-mail: hwexler{at}ucla.edu.


Antimicrobial Agents and Chemotherapy, November 2002, p. 3669-3675, Vol. 46, No. 11
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.11.3669-3675.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2002 by the American Society for Microbiology. All rights reserved.